Data as of Jan 30
| +35.91 / +10.17%|
The 21 analysts offering 12-month price forecasts for Biogen have a median target of 401.00, with a high estimate of 495.00 and a low estimate of 325.18. The median estimate represents a +3.04% increase from the last price of 389.16.
The current consensus among 25 polled investment analysts is to Buy stock in Biogen. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.